DDInter1042 DDInter1724
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole {u} (Compound) resembles {v} (Compound) Sulfisoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP2C8
Sulfamethoxazole {u} (Compound) upregulates {v} (Gene) SLC1A4
Sulfamethoxazole {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Purpura
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracaine
Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Sulfamethoxazole (Compound) binds CYP2C8 (Gene)
Sulfamethoxazole (Compound) upregulates SLC1A4 (Gene)
Sulfamethoxazole (Compound) is included by Sulfonamides (Pharmacologic Class)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene)
Sulfamethoxazole (Compound) causes Purpura (Side Effect)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine